Drug Profile

Zinc monocysteine

Alternative Names: AEN-100; AEN-100/AEN-200; reaZin; Zinc cysteine - Adeona

Latest Information Update: 14 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adeona Pharmaceuticals
Developer Theriva Biologics
Class Antidementias; Cysteines; Zinc compounds
Mechanism of Action Antioxidants; Free radical scavengers; Glutathione peroxidase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

12 Oct 2022 Synthetic Biologics is now called Theriva Biologics
16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
30 Nov 2011 Efficacy and adverse events data from a phase I/II trial in Amyotrophic lateral sclerosis released by Adeona (ADNM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com